Why Three Signaling Species Matter: The IL-17A/F Heterodimer Rationale

The mechanistic case for IL-17A/F bispecific antibodies rests on a single, underappreciated fact: the IL-17 cytokine system produces not one but three biologically active signaling species. The IL-17A homodimer is the primary pro-inflammatory lymphokine of Th17 cells — a CD4+/CD8+ memory effector T cell subset — and has long been the dominant therapeutic target. But foundational work from Wyeth (now Pfizer) established that the IL-17F homodimer and the IL-17A/IL-17F heterodimer are also naturally occurring, biologically active entities capable of independently driving inflammatory cytokine secretion from fibroblasts and keratinocytes, both signaling through the IL-17RA/IL-17RC receptor complex.

This distinction is not merely academic. Selective IL-17A blockade — the mechanism of secukinumab and ixekizumab — leaves the IL-17F homodimer and the heterodimer free to continue driving inflammation. Retrieved data from Sinocelltech confirm that blocking IL-17A/F binding to IL-17RA, rather than IL-17A alone, produces superior suppression of inflammatory cytokine secretion in human foreskin fibroblast (HFF) assays. The rationale for dual blockade is therefore not additive — it targets a third biochemically distinct signaling unit that monospecific agents structurally cannot address.

The receptor architecture reinforces this logic. IL-17RA — the shared receptor chain for IL-17A, IL-17F, and the heterodimer — can itself be targeted to achieve pan-IL-17 blockade, as Amgen’s brodalumab-class antigen-binding proteins demonstrate. However, receptor-level blockade sacrifices ligand selectivity, which may affect the safety profile compared to targeted IL-17A/F dual blockade at the cytokine level. According to WIPO patent records, this mechanistic distinction has generated parallel and competing IP strategies across multiple jurisdictions since the mid-2000s.

Bimekizumab and the Bispecific IP Landscape

Bimekizumab (UCB Biopharma) is the most clinically advanced and IP-rich anti-IL-17A/F bispecific antibody in this dataset. Its mechanism — simultaneous binding to antigenic determinants on both human IL-17A and human IL-17F — neutralises the IL-17A homodimer, the IL-17F homodimer, and the IL-17A/F heterodimer within a single molecule. UCB Biopharma holds an active and expanding global patent portfolio spanning Australian, European, Japanese, Singaporean, Indian, and Chilean jurisdictions, with filings dated 2018–2023.

“Dual neutralization of IL-17A and IL-17F in a single molecule targets a third biochemically distinct signaling unit — the IL-17A/F heterodimer — that selective IL-17A blockade structurally cannot address.”

UCB Biopharma’s IP position in this dataset is effectively a near-exclusive one for the anti-IL-17A/F bispecific format. Competitors seeking to enter the space must design around UCB’s composition-of-matter and treatment method claims, or target distinct epitope combinations or molecular formats. The Wyeth/Pfizer foundational patents on heterodimer biology (filed 2008–2011) are now largely inactive, potentially freeing certain downstream claims — but freedom-to-operate analysis remains essential given the breadth of UCB’s active use claims across jurisdictions.

NovImmune SA (subsequently acquired) filed patents on fully human monoclonal antibodies selective for IL-17F and/or the IL-17A/IL-17F heterodimer but not IL-17A — a complementary rather than overlapping approach to bimekizumab. UCB Biopharma has also filed a multispecific patent (2022, Indonesia) describing antibodies with binding specificity for human IL-13, IL-17A, and/or IL-17F, signalling a potential next-generation triple-specificity product strategy for complex inflammatory skin diseases where Th2 (IL-13) and Th17 (IL-17A/F) pathways co-exist.

Monospecific and Receptor-Level Competitors: Secukinumab, Ixekizumab, and Brodalumab

Selective IL-17A blockade remains the dominant comparator modality across the retrieved patent dataset. Secukinumab (Novartis, IgG1/κ) binds the IL-17A homodimer at a precisely characterised cross-chain epitope spanning residues Leu74, Tyr85, His86, Met87, Asn88, and Val124–His129 on one chain and Tyr43, Tyr44, Arg46, Ala79, and Asp80 on the other. Its binding affinity is approximately KD 100–200 pM, with an IC50 of approximately 0.4 nM for 0.67 nM human IL-17A in vitro and a plasma half-life of approximately four weeks.

Novartis AG is the most prolific assignee in the broader dataset, with extensive filings across Japanese, Israeli, Singaporean, Canadian, WO, and Taiwanese jurisdictions for secukinumab across plaque psoriasis, PsA, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and generalised pustular psoriasis. Filings span 2012–2025, indicating continued portfolio prosecution and label expansion. A 2018 WO filing describes long-term IL-17A blockade potentially converting moderate-to-severe psoriasis to mild disease — a disease-modification claim that, if extrapolated to IL-17A/F dual blockade, could substantially extend the therapeutic and IP value proposition of bimekizumab.

Ixekizumab (Eli Lilly) represents a second selective IL-17A comparator, with dose regimen and formulation patents filed in Japanese and WO jurisdictions for psoriasis, PsA, and ankylosing spondylitis. At the receptor level, Kirin-Amgen’s brodalumab-class antigen-binding proteins block all IL-17RA-utilising ligands — achieving pan-IL-17 blockade at the cost of ligand selectivity. According to published data from the European Medicines Agency, this broader mechanism has been associated with a distinct safety monitoring requirement not observed with cytokine-selective agents.

The upstream IL-23/Th17 axis represents a mechanistically distinct competitive approach. Janssen Biotech’s guselkumab (anti-IL-23/p19) filings through 2026 reference clinical data showing PASI90, PASI100, IGA 0/1, ACR20/50/70, MDA, HAQ-DI, and structural endpoint improvements at weeks 16–48 — with one retrieved filing explicitly claiming superiority of guselkumab over secukinumab at weeks 24–48. This upstream blockade prevents IL-17 production entirely, providing a mechanistic alternative that competes commercially with direct IL-17A/F dual blockade.

Hidradenitis Suppurativa: The Emerging Priority Indication

Hidradenitis suppurativa (HS) is an underdeveloped but rapidly emerging indication for IL-17A/F dual blockade, and the patent evidence suggests it may become a priority area within the next development cycle. HS is characterised by a complex, mixed cytokine environment involving Th1, Th2, and Th17 pathways simultaneously — a landscape where selective IL-17A blockade may be insufficient to achieve deep clinical response.

UCB Biopharma’s Australian and European bimekizumab patent filings explicitly include HS alongside psoriasis and PsA in treatment method claims — a deliberate IP positioning that signals commercial intent for this indication. The MoonLake Immunotherapeutics biomarker patent further describes methods for identifying “super-responders” to IL-17-targeted therapy in HS, introducing a precision medicine layer that could enable label-enabling differentiation for IL-17A/F bispecific agents in this indication.

The unmet need in HS is substantial. Approved anti-TNF biologics do not adequately address moderate-to-severe HS in a significant proportion of patients, and the IL-17 pathway’s role in follicular occlusive inflammation — the defining pathological process of HS — provides a strong mechanistic rationale for dual IL-17A/F blockade. Research published by Nature and cited by immunodermatology groups confirms that IL-17A and IL-17F are both elevated in HS lesional tissue, supporting the therapeutic hypothesis that dual neutralisation may achieve superior clinical signal compared to selective IL-17A inhibition alone.

Next-Generation Multispecifics, Oral Inhibitors, and the Competitive Frontier

The IL-17A/F bispecific space is not static. Retrieved patent evidence signals at least four distinct next-generation competitive vectors that drug developers and IP strategists should monitor closely.

Triple-Specificity: IL-13 + IL-17A + IL-17F

UCB Biopharma’s 2022 Indonesian patent describes multispecific antibodies with binding specificity for human IL-13, IL-17A, and/or IL-17F. IL-13 drives Th2-skewed atopic inflammation, while IL-17A/F drives Th17 pathology — both are relevant to HS, which exhibits a mixed Th1/Th2/Th17 cytokine environment, and to certain psoriasis endotypes. This triple-specificity approach signals a potential next-generation product strategy for complex inflammatory skin diseases where single-pathway blockade is insufficient.

IL-17A + TNF-α Dual Targeting

Y-Biologics Inc. (Korea) filed a 2022 Japanese patent describing a bispecific antibody co-neutralising IL-17A and TNF-α, claiming rapid inflammation suppression via simultaneous inhibition of two non-redundant pathways. This approach is mechanistically relevant to PsA and HS, where TNF-α also drives disease, and represents competitive pressure on bimekizumab from a TNF co-targeting angle. Standards bodies including ISO have begun formalising bispecific antibody characterisation frameworks that will govern how these agents are assessed in regulatory submissions.

Oral Small Molecule IL-17 Modulators

Janssen Pharmaceutica NV filed two patent families (2023–2024) describing orally administered imidazolidazine and imidazopyridazine compounds as IL-17 modulators. If these advance clinically, they would represent a modality shift competitive with injectable bispecific antibodies — particularly for patients with mild-to-moderate disease or injection-averse populations. According to the US FDA, oral small molecule biologics have historically achieved faster uptake in patient populations where injection burden is a barrier to adherence.

Biomarker-Guided Precision Medicine in HS

MoonLake Immunotherapeutics’ 2025 biomarker patent introduces a precision medicine layer to IL-17-targeted HS therapy, enabling patient stratification, super-responder identification, and treatment monitoring. This approach could enable label-enabling differentiation for IL-17A/F bispecific agents in HS and represents a translational strategy that competitors without equivalent biomarker data will find difficult to replicate quickly.

Strategic Implications for Drug Developers and IP Teams

The IL-17A/F bispecific antibody space presents a concentrated IP landscape with clear strategic implications for developers, investors, and IP counsel across the psoriasis, PsA, and HS indications.

• UCB Biopharma holds a near-exclusive IP position for anti-IL-17A/F bispecific antibodies (bimekizumab) across multiple jurisdictions in this dataset, including psoriasis, PsA, axial spondyloarthritis, and HS. Competitors entering the bispecific IL-17A/F space must design around UCB’s composition-of-matter and treatment method claims, or target distinct epitope combinations or molecular formats.
• The IL-17A/F heterodimer is a legally and biologically distinct target from the IL-17A homodimer. Foundational Wyeth/Pfizer IP on heterodimer biology (2008–2011) is now largely inactive, potentially freeing certain downstream therapeutic claims — but freedom-to-operate analysis remains essential given the breadth of UCB’s active use claims.
• HS is an underdeveloped but rapidly emerging indication. MoonLake’s 2025 biomarker patent and UCB’s explicit inclusion of HS in treatment method claims signal that this may become a priority indication, particularly given unmet need in moderate-to-severe HS not adequately addressed by approved anti-TNF biologics.
• The IL-23/IL-17 axis competition (Janssen guselkumab vs. UCB bimekizumab) represents a mechanistic and commercial divide between upstream IL-23 blockade and downstream dual IL-17A/F neutralisation. Guselkumab’s claimed superiority over secukinumab at PASI90/100 endpoints at weeks 24–48 suggests the IL-23 pathway may achieve comparable efficacy via a distinct mechanism.
• Next-generation multispecific antibodies and oral small molecule IL-17 inhibitors represent the emerging competitive frontier. Drug developers and investors should assess how bimekizumab’s clinical profile compares against these emerging modalities, particularly in HS where the cytokine milieu is more complex than in plaque psoriasis.
• Sinocelltech’s humanised anti-IL-17A programme (2022–2024, multiple jurisdictions) is at IND-enabling preclinical stage, with cynomolgus monkey PK data and in vivo psoriasis mouse model efficacy data, representing a potential biosimilar or next-generation monospecific entrant from China.

“HS is an underdeveloped but rapidly emerging indication for IL-17A/F dual blockade — MoonLake’s 2025 biomarker patent and UCB’s explicit HS treatment method claims signal that this may become a priority indication within the next development cycle.”

The overall picture is one of a maturing but still rapidly evolving field. UCB’s bimekizumab has established the clinical and IP proof of concept for IL-17A/F dual blockade; the next competitive wave will likely come from multispecific formats that add additional cytokine targets (IL-13, TNF-α), from oral small molecules that shift the modality entirely, and from biomarker-stratified precision medicine approaches that redefine who responds to IL-17-targeted therapy. IP teams and R&D leaders should use tools such as PatSnap’s life sciences intelligence platform to continuously monitor freedom-to-operate risk, assignee activity, and emerging claim landscapes in this space.